Separate the source’s statement from our interpretation. Date both. Keep a correction trail.
Submission range: January 1–March 31, 2027. For each endpoint add 60 calendar days, then 10 calendar months for standard or 6 for hypothetical priority review. Publish rounded month ranges rather than false day-level precision. No probability is attached. A verified agency/sponsor-announced target action date supersedes the scenario, not the approval uncertainty.
Website-export mode only: use one Google Trends CSV covering a full, consistently selected window for the term “retatrutide,” U.S., Web Search, All categories. Keep 52 completed weekly observations from the same extraction. The displayed index is the latest complete week. Compare the most recent four-week mean with the preceding four-week mean in the same extraction. Suppress the comparison for missing/censored data or a baseline mean below 5. This floor is an editorial stability rule, not a Google standard.
Archive the original export, extraction date, settings, data coverage and SHA-256. Never splice normalized exports, call the index absolute search volume, infer purchase intent or feed it into the regulatory model. No source data is loaded in this prototype.
Retatrutide is not a component of an FDA-approved drug; FDA states it cannot be used in compounding under federal law.
Publication: See agency page; page is updated · Checked: 2026-09-14
Lilly describes its planned retatrutide application as a BLA and plans submission in Q1 2027. This is a company plan, not FDA acceptance or approval.
Publication: 2026-08-05 · Checked: 2026-09-14
Sponsor announcement of TRIUMPH-2 and TRIUMPH-3 topline results and intended Q1 2027 filing. Not an FDA determination.
Publication: 2026-07-23 · Checked: 2026-09-14
For original BLAs and NME NDAs, standard and priority goals are 10 and 6 months respectively after the 60-day filing date. These are action goals, not promised approvals.
Publication: FY 2023–2027 framework · Checked: 2026-09-14
Priority review is an FDA designation; it is not assumed from publicity or commercial interest.
Publication: See agency page · Checked: 2026-09-14
Trial listings are not federal endorsement; participation requires discussion of risks and potential benefits.
Publication: 2025-04-24 · Checked: 2026-09-14
Route to original registry records. No recruiting status or eligibility is reproduced in this prototype.
Publication: Records change individually · Checked: 2026-09-14
Official search excerpt states Lilly supports individual requests subject to criteria and geography. Full eligibility text was not accessible in the research tool; recheck at publication.
Publication: Not established from retrieved page · Checked: 2026-09-14
Expanded access is a distinct investigational pathway, not general commercial approval.
Publication: See agency page · Checked: 2026-09-14
Express and implied health claims require appropriate substantiation; disclaimers cannot cure a contradictory overall impression.
Publication: 2022 guidance · Checked: 2026-09-14
Advertising must be recognizable; necessary disclosures must be clear and prominent. Search-index text retrieved; full page fetch unavailable.
Publication: 2015-12-21 · Checked: 2026-09-14
Accurate identity and subject lines, required commercial-email disclosures, postal address and functioning opt-out.
Publication: See agency page · Checked: 2026-09-14
Collection and sharing rules, exceptions and consent disclosure requirements. Applicability requires review of actual data flows.
Publication: Current code retrieved · Checked: 2026-09-14
Definitions, notices, rights, security, processors, and distinct authorization requirements for sales, with statutory exceptions.
Publication: Current code retrieved · Checked: 2026-09-14
Website data are sampled/normalized relative search-interest indices, not absolute search counts or purchase intent.
Publication: See Google Help · Checked: 2026-09-14
CSV export and attribution support a low-cost manual update workflow.
Publication: See Google Help · Checked: 2026-09-14
Access remains application-based alpha; the API scaling differs from website 0–100 exports. Do not assume credentials or equivalent scales.
Publication: Current documentation · Checked: 2026-09-14
Indexing or archiving is not NIH endorsement of a study or a product.
Publication: See NLM page · Checked: 2026-09-14
Restrictions address sponsors, investigators and persons acting on their behalf; scientific exchange is distinguished from promotion. Manufacturer control/sponsorship requires renewed review.
Publication: Code current to 2026-09-10 in retrieved page · Checked: 2026-09-14
Retrieved 2026-09-16. Self-declared 'verified providers' and 'Trusted by thousands monthly' claims without visible methodology or audit reference. Substantiated efficacy comparisons (semaglutide 15–20% body-weight loss; tirzepatide 22–26%) presented without specific citations. Hold promotion pending visible verification backbone and source-linked efficacy figures.
Publication: Live retrieval · Checked: 2026-09-16
Retrieved 2026-09-16. Root page lists retatrutide alongside FDA-approved peptides (BPC-157, Tirzepatide, Semaglutide) as a 'verified offering.' This contradicts RetaFinder's position that retatrutide is investigational and cannot be compounded under federal law (see S01). Embedded clinic data appears to be auto-generated from the TRT-Finder Airtable sync without peptide-specific verification. Hold promotion pending retatrutide removal or clear investigational-only framing.
Publication: Live retrieval · Checked: 2026-09-16
Retrieved 2026-09-16. Page asserts HRT is 'the most effective treatment for menopausal symptoms' and recommends A4M certification as a provider-selection signal, both without specific source citations. Approved-versus-off-label-versus-compounded distinctions are not drawn. Hold promotion pending source attribution for efficacy claim, A4M reference reframed or removed, and clearer approved/off-label/compounded framing.
Publication: Live retrieval · Checked: 2026-09-16
Retrieved 2026-09-16. Verification backbone disclosed: MedVerity by Signal Loom AI, cross-checked against NPI Registry, state medical boards and federal sources. Specific counts disclosed (375+ providers, 30+ telemedicine, 190+ in-person). Common-ownership disclosure: AIM Elemental Group / HormoneVentures, LLC. Sister-publisher disclosure: AEGCompliance. Clear disclaimer: 'not a medical referral service.' No implied cure or comparative efficacy claims on the root page. Approved 2026-09-16 for sponsored outbound with adjacent relationship disclosure.
Publication: Live retrieval · Checked: 2026-09-16
Avoid doorway sites, scaled low-value pages and link schemes; useful original editorial content is the proposed strategy.
Publication: Current documentation · Checked: 2026-09-14
Defines application types and where each pathway applies. Biologic peptide therapeutics use the BLA pathway.
Publication: See agency page · Checked: 2026-09-15
510(k) is the medical-device clearance pathway; it is not the drug application pathway. Included for completeness because the term appears in combination-product and device coverage.
Publication: See agency page · Checked: 2026-09-15
Breakthrough designation criteria, process and effect on review. Distinct from priority review and accelerated approval.
Publication: See agency page · Checked: 2026-09-15
Fast track criteria, sponsor-agency interaction frequency and review effect. Distinct from breakthrough, priority review and accelerated approval.
Publication: See agency page · Checked: 2026-09-15
Approval based on surrogate or intermediate endpoints reasonably likely to predict clinical benefit; post-marketing confirmatory trials typically required.
Publication: See agency page · Checked: 2026-09-15
REMS may impose prescribing, dispensing, or monitoring requirements; not all approved drugs carry a REMS.
Publication: See agency page · Checked: 2026-09-15